[Diagnosis and Treatment of Liver Dysfunction with Immune Checkpoint Inhibitors]

With the advent of immune checkpoint inhibitors(ICIs), the standard treatment for advanced cancer is changing significantly. While ICI is expected to be more effective than conventional treatments, immune-related adverse events(irAEs)such as autoimmune diseases and inflammatorydiseases mayoccur. Therefore, the management different from the side effects of conventional cytotoxic chemotherapy is necessary. Although many of the liver dysfunctions due to irAE are of low grade, cases of Grade 3 or higher have been reported. The point of management for irAE is earlyappropriate treatment according to early diagnosis and management algorithm. In the treatment of liver dysfunction due to irAE, corticosteroids are used as the firstline drug, and other immunosuppressive agents are examined when the effects of steroids are insufficient. Liver dysfunction caused byirAE can lead to fatal or irreversible damage if delayed and severe, but there are manythings that can be managed if diagnosed earlyand given appropriate treatment. In the future, with the expansion of applicable cancer types and the introduction of combination therapywith different ICI combinations and molecular target drugs, specialists in digestive organs or liver will join the ICI treatment team to conduct appropriate liver dysfunction management at an early stage. It is thought that it will become more and more important.